Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Health Canada/OCTASA

Authorized

STANDARD

OCTASA

Tillotts Pharma Ag🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: fdac6ce5979339ac
Company: Tillotts Pharma Ag
Type: Standard

Approval Details

Approval Id: fdac6ce5979339ac
Drug Approval Canada Name: OCTASA
Product Name: OCTASA
Status: Marketed
Status Date: 2022-09-28
Original Market Date: 2022-09-28
Din: 02465752
Drug Class: Human
Dosage Form: Tablet (Delayed-Release)
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 56:36.00
Atc Original: A07EC02 MESALAZINE
Atc Name: a 07 ec 02
Aig Number: 0116808010
Company Name: Tillotts Pharma Ag
Company Address: Baslerstrasse 15, Rheinfelden, Aargau, Switzerland, 4310
Company Detail Path: /organization/tillotts-pharma-ag

Company Information

Pharmaceutical Company Name: Tillotts Pharma Ag
Country Name: Sweden
Address: Utländsk Adr - Foreign Addr
Website: http://www.tillotts.com

Active Ingredients

MESALAZINE

800 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

fdac6ce5979339ac

Type

Standard

Back to Health Canada Approvals

OCTASA - Health Canada Drug Approval Details